Israel Active

Researchers at Israel’s Sheba Medical Center and Volcani Institute have developed a powder made from unripe peanuts that weans children off peanut allergies. There are no allergenic proteins in unripe peanuts, and food made from their powder (cookies, pancakes etc.) will slowly desensitize the allergy.

Israel’s RedDress (see previously) is saving lives with its ActiGraft bandage for chronic wounds in over 30 countries, including Brazil, Turkey, and France. In Israel, it is available to patients of Clalit - the country’s largest health maintenance organization.

Israel’s IR-Med has developed an AI device powered by infrared light spectroscopy that spots pressure injuries, bedsores, and ulcers at an early stage. The PressureSafe device noninvasively detects them, preventing infections and even saving lives.

Israeli-founded TrainPain won the Grand Prize in the American Academy of Pain Medicine (AAPM) & MIT Hacking Medicine Innovation Challenge. TrainPain measures and retrains sensory neuroplasticity through home-based haptic (body-movement) mobile games, remote monitoring, and training.

Researchers at Tel Aviv University and UCLA have shown that long-lasting memories are consolidated during sleep by communication between the hippocampus and the cerebral cortex. Deep-brain stimulation during sleep improves memory consolidation and provides hope for dementia patients.

Jerusalem’s Shaare Zedek Medical Center has just opened its new state-of-the art Helmsley Cancer Center. The 12,000-square-meter center houses all Shaare Zedek’s medical, radiotherapy, counseling, spiritual and palliative oncological services under one roof.

Israel’s Belong.Life (see previously) has launched “Dave” – the world's first AI chatbot for cancer patients. Its purpose is to improve access to quality cancer care for patients around the world. It is available free of charge on Belong. Life’s Beating Cancer Together app. “Be well, Belong”.

From 1st Sep, Israeli patients will be able to pick the hospital of their choice to undergo free or subsidized treatments in neurosurgery, mental health services, gynecological surgery, and in-vitro fertilization. They can already choose hospitals for oncology and obstetrics.

Israel’s BioNanoSim (see previously) is joining forces with Greek-based manufacturer RAFARM, to market BioNanoSim’s eye disease treatments globally. Its product, BNSO-1, is a topical medication that will shortly begin trials on patients suffering from Chronic Anterior Uveitis.

Ben-Gurion University researchers have partnered Israel’s OncoHost to develop a biosensor that safely predicts if anti-PD1 therapy may cure a specific cancer patient. The leading immune checkpoint inhibitor (ICI) therapy is invasive and other treatments may be better. (see also ).